NEW ASPECTS OF TREATING CHRONIC PAIN: MULTICENTER, OPEN-LABEL CLINICAL TRIAL OF MEDICATION KETONAL DUO IN PATIENTS WITH DEGENERATIVE JOINT DISEASES
https://doi.org/10.14412/1995-4484-2014-195-201
Abstract
The results of multicenter, open-label trial aimed at assessing the effectiveness, safety, and compliance of medication Ketonal Duo in 602 patients with osteoarthritis (OA) are presented. The trial duration was 28 days. The medication demonstrated a reliable analgesic effect and good tolerance; adverse events were observed in 4.7% of patients. The effect was observed in 97.9% of patients with OA according to the physician's opinion and in 99.1% as reported by the patients. Most patients and physicians consider the medication to have maximal convenience.
About the Authors
N. V. Chichasova
Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation, Moscow, Russia
Russian Federation
Russian Federation
R. G. Kamalova
Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation, Moscow, Russia
Russian Federation
Russian Federation
T. V. Plaksina
Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation, Moscow, Russia
Russian Federation
Russian Federation
A. A. Popov
Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation, Moscow, Russia
Russian Federation
Russian Federation
References
1. Smith MM, Ghosh P. Osteoarthritis: Current status and future directions. APLAR J Rheum. 1998;2:27–53.
2. Lawrence RC, Brummer JM, Bier F. Osteoarthritis prevalence in the population and relationship between symptoms and x-ray
3. changes. Ann Rheum Dis. 1966;25(1):1–24.
4. Sokka T, Pincus T. Abstract presented during the American College of Rheumatology 2005 Scientific Sessions. San Diego, California; 2005.
5. Emery P. Considerations for nonsteroidal anti-inflammatory drug therapy: benefits. Scand J Rheumatol Suppl. 1996;105:5–9; discus sion 10–2. DOI: http://dx.doi.org/10.3109/03009749609097231.
6. Richy F, Bruyere O, Eihgen O, et al. Time dependent risk of gas- trointestinal complications induced by non-steroidal anti-inflam-
7. matory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63(7):759–66. DOI: http://dx.doi.org/10.1136/ard.2003.015925.
8. Насонов ЕЛ, Лазебник ЛБ, Беленков ЮН и др. Применение нестероидных противовоспалительных препаратов.
9. Клинические рекомендации. Москва: Алмаз; 2006. 88 с.
10. [Nasonov EL, Lazebnik LB, Belenkov YuN, et al. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomen-
11. datsii [Application of nonsteroid anti-inflammatory preparations. Clinical recommendations]. Moscow: Almaz; 2006. 88 p.]
12. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Int Med. 2000;160(6):777–84. DOI: http://dx.doi.org/10.1001/arch- inte.160.6.777.
13. Heerdink ER, Leufkens HG, Herings RMC, et al. NSAIDs associated with increase risk of congestive heart failure in elderly patients taking diuretics. Arch Int Med. 1998;158(10):1108–12. DOI: http://dx.doi.org/10.1001/archinte.158.10.1108.
14. Каратеев АЕ, Коновалова НН, Литовченко АА и др. НПВП- ассоциированное заболевание желудочно-кишечного тракта при ревматизме в России. Клиническая медицина. 2005;83(5):33–8. [Karateyev AYe, Konovalova NN, Litovchenko AA, et al. A NSAID-asso-ciated alimentary tract disease in patients with rheu-matism in Russia. Klinicheskaya meditsina. 2005;83(5):33–8. (In Russ.)]
15. Helin-Salmivaara A, Saarelainen S, Grö nroos JM, et al. Risk
16. of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scand J Gastroenterol. 2007;42(8):923–32. DOI: http://dx.doi.org/10.1080/00365520701192326.
17. Наумов АВ, Верткин АЛ, Мендель ОВ и др. Как повысить безопасность и эффективность «антиартрозной» терапии у больных с соматической патологией. Русский медицинский журнал. 2007;15(26):2012–9. [Naumov AV, Vertkin AL, Mendel' OV, et al. How to increase safety and efficiency of «antiartrozny» therapy at patients with somatic pathology. Russkii meditsinskii zhurnal. 2007;15(26):2012–9. (In Russ.)]
18. Чичасова НВ, Насонов ЕЛ, Имаметдинова ГР. Применение кетопрофена (Кетонал) в лечебной практике. Фарматека. 2003;5(68):30–2. [Chichasova NV, Nasonov EL, Imametdinova GR. Primenenie ketoprofena (Ketonal) v lechebnoi praktike. Farmateka [Application of ketoprofen (Ketonal) in medical prac- tice. Farmateka]. 2003;5(68):30–2.]
19. Williams RL, Upton RA. The clinical pharmacology of ketopro- fen. J Clin Pharm. 1988; (12 Suppl):S13–22. DOI: http://dx.doi.org/10.1002/j.1552–4604.1988.tb05971.x.
20. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20000 patients. Scand J Rheum. 1989;83:21–7. DOI:
21. http://dx.doi.org/10.3109/03009748909101474.
22. Ветшев ПС, Ветшева МС. Принципы анальгезии в раннем послеоперационном периоде. Хирургия. 2002;(12):49–52. [Vetshev PS, Vetsheva MS. The principles of an analgeziya in the early postoperative period. Khirurgiya. 2002;(12):49–52. (In Russ.)]
23. Новиков ГА, Вайсман МА, Прохоров БМ и др. Кетонал в лечении болевого синдрома у пациентов с распространенными формами злокачественных новообразований. Паллиативная медицина и реабилитация. 2002;(3):48–51. [Novikov GA, Vaisman MA, Prokhorov BM, et al. Ketonal in treatment of a pain syndrome at patients with wide- spread forms of malignant new growths. Palliativnaya meditsina i reabilitatsiya. 2002;(3):48–51.(In Russ.)]
24. Айламазян ЭК, Ниаури ДА, Зиятдинова ГМ. Клинико- экономическое обоснование применения кетонала с целью обезболивания после эндоскопических вмешательств в гинекологии. Российский вестник акушера-гинеколога. 2002;(6):51–3. [Ailamazyan EK, Niauri DA, Ziyatdinova GM. Application Cliniko-economic justification ketanol for the purpose of anesthesia after endoscopic interventions in gynecology. Rossiiskii vestnik akushera-ginekologa. 2002;(6):51–3. (In Russ.)]
25. Haskisson EC. Clinical aspects of chondroprotection. Semin Arthritis Rheum. 1990 Feb;19(4 Suppl 1):30–2. DOI: http://dx.doi.org/10.1016/0049-0172(90)90083-R.
26. Doherty M. Chondroprotection by nonsteroidal anti-inflammato- ry drugs. Ann Rheum Dis. 1989;48(8):619–21. DOI: http://dx.doi.org/10.1136/ard.48.8.619.
27. Brandt KD. The mechanism of action of nonsteroidal antiinflam- matory drugs. J Rheumatol Suppl. 1991;27:120–1.
28. Ostensen M. Cartilage changes in arthritis do non-steroidal antiphlogistics have positive or negative effects? Tidsskr Nor Laegeforen. 1991;111(7):838–40.
29. Manicourt DH, Pita JC. Progressive depletion of hyaluronic acid in early experimental osteoarthritis in dogs. Arthritis Rheum. 1988;31(4):538–44. DOI: http://dx.doi.org/10.1002/art.1780310411.
30. Sweet MB, Thonar EJ, Immelman AR, Solomon L. Biochemical changes in progressive osteoarthrosis. Ann Rheum Dis. 1977;36(5):387–98. DOI: http://dx.doi.org/10.1136/ard.36.5.387. 24. Thonar EJ, Sweet MB, Immelman AR, Lyons G. Hyaluronate in
31. articular cartilage: age-related changes. Calcif Tissue Res. 1978;26(1):19–21. DOI: http://dx.doi.org/10.1007/BF02013228. 25. Holmes MW, Bayliss MT, Muir H. Hyaluronic acid in human articular cartilage. Age-related changes in content and size. Biochem J. 1988;250(2):435–41.
32. Blot L, Marcelis A, Devogelaer JP, Manicourt DH. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of pro- teoglycans and hyaluronan in osteoarthritic human articular carti- lage. Br J Pharmacol. 2000;131(7):1413–21. DOI: http://dx.doi.org/10.1038/sj.bjp.0703710.
33. Huber-Brunning O, Willbrinck B, Vanroy J, Vanderveen MJ. Potential influences of ketoprofen on human healthy and osteoarthritic cartilage in vitro. Scand J Rheumatol Suppl. 1989;83:29–32. DOI: http://dx.doi.org/10.3109/03009748909101475.
34. Чичасова НВ, Имаметдинова ГР. Симптом- модифицирующая терапия ОА: возможности Кетонала ДУО. Consilium medicum. 2010;(2):30–5. [Chichasova NV, Imametdinova GR. Simptom-modifitsiruyushchaya terapiya OA: vozmozhnosti Ketonala DUO. Consilium medicum. 2010;(2):30–5.]
35. Шостак НА, Рябкова АА, Бабадаева НМ. Сравнительная эффективность нестероидных противовоспалительных препаратов при болях в спине. Русский медицинский журнал, ревматология. 2003;11(15):860–2. [Shostak NA, Ryabkova AA, Babadaeva NM. Comparative efficiency of nons- teroid anti-inflammatory preparations at a back pains. Russkii meditsinskii zhurnal, revmatologiya. 2003;11(15):860–2. (In Russ.)]
36. Чичасова НВ, Каневская МЗ, Имаметдинова ГР, Иголкина ЕВ. Кетопрофен в лечении хронических воспалительных заболеваний суставов. Consilium Medicum. 2007;9(8):124–8. [Chichasova NV, Kanevskaya MZ, Imametdinova GR, Igolkina EV. Ketoprofen in treatment of chronic inflammatory diseases of joints. Consilium Medicum. 2007;9(8):124–8. (In Russ.)]
37. Morley KD, Bernstein RM, Hughes GRV, et al. A comparative trial of a controlled-release formulation of ketoprophen and a con- ventional capsule formulation of ketoprophen in patients with osteoarthritis of the hip. Curr Med Res Opin. 1984;9(1):28–34. DOI: http://dx.doi.org/10.1185/03007998409109555.
Review
For citations:
Chichasova N.V., Kamalova R.G., Plaksina T.V., Popov A.A. NEW ASPECTS OF TREATING CHRONIC PAIN: MULTICENTER, OPEN-LABEL CLINICAL TRIAL OF MEDICATION KETONAL DUO IN PATIENTS WITH DEGENERATIVE JOINT DISEASES. Rheumatology Science and Practice. 2014;52(2):195-201. (In Russ.) https://doi.org/10.14412/1995-4484-2014-195-201
Views:
1192
Email this article 